<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raymond R Townsend, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George L Bakris, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William J Elliott, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 11, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are widely used in the treatment of hypertension, chronic kidney disease, and heart failure. In addition to efficacy, these agents have the additional advantage of being particularly well tolerated since they produce few idiosyncratic side effects and do not have the adverse effects on lipid and glucose metabolism seen with higher doses of diuretics or beta blockers [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3867.html" rel="external">
          "Antihypertensive drugs and lipids"
         </a>
         .)
        </p>
        <p>
         The specific side effects that are observed with ACE inhibitors and ARBs will be reviewed here. The use of these drugs in disorders such as hypertension, heart failure, and proteinuric chronic kidney disease are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">
          "Renin-angiotensin system inhibition in the treatment of hypertension"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3873.html" rel="external">
          "Renal effects of ACE inhibitors in hypertension"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">
          "Treatment of diabetic kidney disease"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Sacubitril-valsartan, ACE inhibitor, or ARB'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The safety of ACE inhibitors and ARBs in patients with coronavirus disease 2019 (COVID-19) is presented in another topic:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/127552.html" rel="external">
          "COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Renin angiotensin system inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ACE INHIBITORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although high-dose
         <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">
          captopril
         </a>
         therapy was initially associated with a variety of presumed sulfhydryl group-related complications such as rash, neutropenia, taste abnormalities, and even the nephrotic syndrome, these problems have become uncommon since the maximum dose was reduced to 100 to 150 mg/day and particularly since clinicians have begun using other angiotensin-converting enzyme (ACE) inhibitors.
        </p>
        <p>
         The side effects that do occur are primarily related directly or indirectly to reduced angiotensin II formation. These include hypotension, acute kidney injury, hyperkalemia, and problems during pregnancy [
         <a href="#rid1">
          1
         </a>
         ]. There are other complications (cough, angioedema, and anaphylactoid reactions) that are thought to be related to increased kinins since ACE is also a kininase (see
         <a class="local">
          'Cough'
         </a>
         below). This is an important distinction clinically because the side effects related to reduced angiotensin II, but not those related to kinins, are also seen with the angiotensin II receptor blockers (ARBs). (See
         <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">
          "Renin-angiotensin system inhibition in the treatment of hypertension"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Hypotension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weakness, dizziness, or syncope may result from an excessive reduction in blood pressure. In the Ongoing
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          Telmisartan
         </a>
         Alone and in Combination With
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          Ramipril
         </a>
         Global Endpoint Trial (ONTARGET), hypotensive symptoms sufficient to discontinue the drug occurred in 1.7 percent of the 8576 patients who received ramipril [
         <a href="#rid3">
          3
         </a>
         ]. First-dose hypotension, which can be marked in hypovolemic patients with high baseline renin levels, can be minimized by not beginning therapy if the patient is volume depleted and/or by discontinuing prior diuretic therapy for three to five days. Hypotension can also occur after the initiation of therapy in patients with heart failure [
         <a href="#rid4">
          4
         </a>
         ]. The risk can be minimized by beginning with a very low dose, such as 2.5 mg BID of
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/3838.html" rel="external">
          "Treatment of hypertension in patients with heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Reduction in GFR
         </span>
         <span class="headingEndMark">
          —
         </span>
         A reduction in glomerular filtration rate (GFR), which is usually modest (approximately 5 to 25 percent) but may be severe (&gt;30 percent), is observed in some patients treated with ACE inhibitors (and other inhibitors of the renin angiotensin system) who have bilateral renal artery stenosis, hypertensive nephrosclerosis, heart failure, polycystic kidney disease, or chronic kidney disease [
         <a href="#rid5">
          5,6
         </a>
         ]. As an example, an elevation in serum creatinine sufficiently severe to warrant discontinuation of the drug occurred in 0.7 percent of the patients who received
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         and 0.8 percent of those who received
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          telmisartan
         </a>
         in the ONTARGET trial, which enrolled patients with vascular disease or high-risk diabetes. A doubling of the serum creatinine in this trial occurred in 1.8 and 1.7 percent, respectively [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3873.html" rel="external">
          "Renal effects of ACE inhibitors in hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2365.html" rel="external">
          "Renal effects of ACE inhibitors in heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1675.html" rel="external">
          "Autosomal dominant polycystic kidney disease (ADPKD): Evaluation and management of hypertension"
         </a>
         .)
        </p>
        <p>
         In each of these disorders, intrarenal perfusion pressure may already be reduced, a setting in which GFR is maintained in part by an angiotensin II-induced increase in resistance at the efferent (postglomerular) arteriole. Blocking this response with an ACE inhibitor (or other inhibitor of the renin angiotensin system) will sequentially relax the efferent arteriole, lower intraglomerular pressure, and reduce GFR [
         <a href="#rid7">
          7
         </a>
         ]. Patients with acute volume loss due to vomiting and/or diarrhea may be particularly susceptible [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The rise in the serum creatinine concentration generally begins a few days after the institution of therapy since angiotensin II levels are rapidly reduced. Thus, kidney function should be checked three to five days after an ACE inhibitor is begun in a patient who has renal artery stenosis or who is at high risk for this problem (as in an older patient with severe hypertension and atherosclerotic vascular disease) [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3825.html" rel="external">
          "Establishing the diagnosis of renovascular hypertension"
         </a>
         .)
        </p>
        <p>
         Even with optimal management, some patients are unable to tolerate ACE inhibitors. Termination of the ACE inhibitor should be considered if hyperkalemia cannot be controlled (see
         <a class="local">
          'Hyperkalemia'
         </a>
         below) or the serum creatinine concentration increases more than 30 percent above the baseline value within the first six to eight weeks when blood pressure is reduced. Such a decline in kidney function is uncommon if the patient is not volume depleted, diuretics have been transiently withheld prior to initiation of therapy, and the patient does not have bilateral renovascular disease. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
         Another rare cause of acute kidney injury that is of unproven relation to ACE inhibitors is the development of renal artery thrombosis [
         <a href="#rid10">
          10
         </a>
         ]. This complication appears to occur most often in patients with marked (≥95 percent) stenotic lesions who have an excessive reduction in blood pressure. It is therefore unclear whether there is any specific predisposing effect of the ACE inhibitor.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Hyperkalemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiotensin II and an elevation in the plasma potassium concentration are the major factors that increase the release of aldosterone, which is the major hormonal stimulus to urinary potassium excretion. In addition to the direct effect of systemic angiotensin II, angiotensin II generated locally within the adrenal zona glomerulosa may mediate the potassium-induced stimulation of aldosterone [
         <a href="#rid11">
          11
         </a>
         ]. Blocking both of these actions with an ACE inhibitor (or ARB) will reduce aldosterone secretion, thereby impairing the efficiency of urinary potassium excretion.
        </p>
        <p>
         The overall incidence of hyperkalemia (defined as a serum potassium concentration above 5.5 mEq/L) in patients treated with an ACE inhibitor or ARB is approximately 3.3 percent [
         <a href="#rid3">
          3
         </a>
         ]. However, there is marked variability in risk. ACE inhibitors and ARBs generally raise the serum potassium concentration by less than 0.5 mEq/L in patients with relatively normal kidney function. More prominent hyperkalemia may be seen in patients with chronic kidney disease, diabetes, concurrent use of a drug promoting potassium retention such as a potassium-sparing diuretic or a nonsteroidal antiinflammatory drug, or among older adults [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p>
         Patients with moderately severe to severe heart failure represent a setting in which multiple factors can contribute to the development of hyperkalemia. These include decreased renal perfusion due to the fall in cardiac output and, often, combined therapy with a mineralocorticoid receptor antagonist (
         <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">
          spironolactone
         </a>
         or
         <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">
          eplerenone
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">
          "Secondary pharmacologic therapy for heart failure with reduced ejection fraction"
         </a>
         .)
        </p>
        <p>
         There is also an increased risk of hyperkalemia among chronic hemodialysis patients who are treated with an ACE inhibitor or ARB. This was shown in a prospective study of 251 hemodialysis patients in which there was an association between a predialysis serum potassium concentration of ≥5.5 mEq/L and the use of an ACE inhibitor or ARB [
         <a href="#rid16">
          16
         </a>
         ]. Use of these agents was associated with an increased risk of hyperkalemia (odds ratio of 2.2, 95% CI 1.4-3.4), which was observed in patients with and without residual kidney function. Dietary measures were the only intervention required to manage the hyperkalemia. Anuria appears to be particularly associated with an increased risk [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_patient" href="/z/d/html/4427.html" rel="external">
          "Patient education: Low-potassium diet (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
         Only one study has assessed the effect on potassium levels of angiotensin blockade in peritoneal dialysis patients. In this report of 29 stable normokalemic peritoneal dialysis patients, the risk of hyperkalemia with either an ACE inhibitor or an ARB was principally observed among those undergoing inadequate dialysis (Kt/V less than 2.0) or with low solute transport characteristics [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         There are several mechanisms by which angiotensin II inhibition can lead to hyperkalemia in patients with end-stage kidney disease: decreased urinary potassium excretion in patients with residual kidney function; and decreased colonic excretion that accounts for a significant percentage of total potassium loss in such patients [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         Among hemodialysis patients first receiving an ACE inhibitor or an ARB, more frequent measurement of the serum potassium concentration should be performed for one month [
         <a href="#rid20">
          20
         </a>
         ]. Once stable, monthly measurements are recommended.
        </p>
        <p>
         Among patients with chronic kidney disease who are not dialysis dependent, issues surrounding the use of ACE inhibitors and hyperkalemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Cough
         </span>
         <span class="headingEndMark">
          —
         </span>
         A dry, hacking cough has been described in 5 to 20 percent of patients treated with an ACE inhibitor [
         <a href="#rid3">
          3,21-23
         </a>
         ]. The best data come from a meta-analysis of 125 trials in which cough was noted in approximately 11 percent of patients treated with ACE inhibitors [
         <a href="#rid23">
          23
         </a>
         ]. Cough is much less common with ARBs. (See
         <a class="local">
          'ARBs'
         </a>
         below.)
        </p>
        <p>
         The cough has the following clinical features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It usually begins within one to two weeks of instituting therapy, but it can be delayed up to six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Females are affected more frequently than males.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It typically resolves within one to four days of discontinuing therapy, but this can take up to four weeks [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It generally recurs with rechallenge, either with the same or a different ACE inhibitor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It does not occur more frequently in patients with asthma, but it may be accompanied by bronchospasm [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The mechanism responsible for the ACE inhibitor-induced cough is not known, but increased local concentrations of kinins, substance P, prostaglandins, or thromboxane may be important:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both kinins and substance P are metabolized by converting enzyme; thus, their levels are increased by converting enzyme inhibition [
         <a href="#rid21">
          21
         </a>
         ]. Kinins, for example, may induce bronchial irritation and cough via enhanced production of prostaglandins, which may then stimulate afferent C-fibers in the airway.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activation of the arachidonic acid pathway with ACE inhibition may also lead to elevated levels of thromboxane, which can potentiate bronchoconstriction. The possible role of thromboxane in ACE inhibitor-induced cough was evaluated in a double-blind crossover study of nine patients who had developed cough while taking
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          enalapril
         </a>
         [
         <a href="#rid26">
          26
         </a>
         ]. The patients were treated with placebo or picotamide (600 mg twice daily), an agent that inhibits thromboxane synthetase and antagonizes the thromboxane receptor. Active therapy resulted in a significant reduction in thromboxane levels and stopped the cough in eight of the nine patients within 72 hours. Inadequate absorption of picotamide occurred in the one nonresponder.
        </p>
        <p>
        </p>
        <p>
         Nonsteroidal antiinflammatory drugs and
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         can reportedly improve the cough related to ACE inhibitors [
         <a href="#rid27">
          27-31
         </a>
         ]. However, these have not been studied in large trials, and some may increase the risk of hyperkalemia, particularly among individuals with decreased kidney function.
        </p>
        <p>
         It remains unclear why cough occurs only in some patients treated with ACE inhibitors. It has been suggested that genetic factors may be important. However, common genetic variants for ACE, the B2 bradykinin receptor, or chymase (another enzyme that can convert angiotensin I to angiotensin II) do not explain the variation in susceptibility to cough.
        </p>
        <p class="headingAnchor" id="H5361360">
         <span class="h3">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the ACE inhibitor is discontinued, improvement often begins within four to seven days [
         <a href="#rid21">
          21
         </a>
         ]. Readministration of an ACE inhibitor is associated with a high rate of recurrent cough (67 percent in a randomized trial) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Patients who have had a good antihypertensive response to the ACE inhibitor can be switched to an ARB since these drugs are associated with a much lower rate of cough than ACE inhibitors [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3936536668">
         <span class="h2">
          Anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         ACE inhibitors (and ARBs) can suppress the production of erythropoietin. This is more likely to occur in the presence of chronic kidney disease due to accumulation of N-acetyl-seryl-aspartyl-lysyl-proline [
         <a href="#rid34">
          34
         </a>
         ], which inhibits stem cell multiplication [
         <a href="#rid35">
          35
         </a>
         ]. Consequently, these drugs can be useful in treating posttransplant erythrocytosis [
         <a href="#rid36">
          36,37
         </a>
         ] or the increase in red cells associated with high altitudes [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7348.html" rel="external">
          "Kidney transplantation in adults: Posttransplant erythrocytosis", section on 'ACE inhibitors or ARBs in all patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Angioedema and anaphylactoid reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angioedema is a rare but potentially fatal complication of ACE inhibitors that, in a large clinical trial (ONTARGET), occurred in 0.3 percent of the more than 8500 patients treated with
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. Half of 111 patients with an initial episode of angioedema while taking an ACE inhibitor had recurrent angioedema after the drug was discontinued, suggesting an underlying mechanism unrelated to the ACE inhibitor [
         <a href="#rid39">
          39
         </a>
         ]. In the Omapatrilat Cardiovascular Treatment vs.
         <a class="drug drug_general" data-topicid="9405" href="/z/d/drug information/9405.html" rel="external">
          Enalapril
         </a>
         (OCTAVE) trial, 86 of 12,557 subjects (0.7 percent) given enalapril experienced angioedema over a 12-week period [
         <a href="#rid40">
          40
         </a>
         ]. The pathogenesis of ACE inhibitor-induced angioedema and the treatment of this condition are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16380.html" rel="external">
          "ACE inhibitor-induced angioedema"
         </a>
         .)
        </p>
        <p>
         Anaphylactoid reactions are also seen when ACE inhibitors are used in patients treated with high-flux hemodialysis using polyacrylonitrile (PAN) dialyzers. (See
         <a class="medical medical_review" href="/z/d/html/1859.html" rel="external">
          "Reactions to the hemodialysis membrane", section on 'Type A reactions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1091593761">
         <span class="h2">
          Drug-induced pancreatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several reports have implicated ACE inhibitors in drug-induced pancreatitis (DIP) [
         <a href="#rid41">
          41-44
         </a>
         ]. As an example, in a large observational study of more than 700,000 patients with hypertension, DIP occurred significantly more frequently with ACE inhibitors than with dihydropyridine calcium channel blockers although absolute rates were low (approximately 0.06 versus 0.04 percent) [
         <a href="#rid42">
          42
         </a>
         ]. By contrast, ARBs were not associated with a higher incidence of DIP. A potential mechanism may be related to the same pathways causing angioedema, resulting in swelling and obstruction of the pancreatic duct [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Contraindication in pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         ACE inhibitors (and other inhibitors of the renin angiotensin system) are contraindicated in pregnancy since they are associated with an increased incidence of fetal complications. (See
         <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">
          "Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Overdose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Manifestations of ACE inhibitor overdosing are usually mild [
         <a href="#rid45">
          45
         </a>
         ]. If, however, severe hypotension occurs, intravenous fluids and inotropic support may be required.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          ARBS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The angiotensin II receptor blockers (ARBs) are typically well tolerated [
         <a href="#rid46">
          46
         </a>
         ]. The side effect profile is generally similar to that seen with angiotensin-converting enzyme (ACE) inhibitors (eg, increased incidence of hyperkalemia and of acute kidney injury in renovascular hypertension or states of effective volume depletion) [
         <a href="#rid3">
          3,16,47,48
         </a>
         ]. The rate of certain side effects (eg, kidney dysfunction, syncope) appears to be similar with the two classes of drugs; however, ARBs have lower rates of cough and angioedema and perhaps a higher rate of hypotensive symptoms than ACE inhibitors.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Incidence of cough with ARBs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of cough is lower in patients treated with ARBs [
         <a href="#rid3">
          3
         </a>
         ]. The magnitude of this difference was illustrated in a 2008 meta-analysis of 29 trials that directly compared the rate of cough in ARBs and ACE inhibitors [
         <a href="#rid33">
          33
         </a>
         ]. The respective rates of cough were 3.2 and 9.9 percent, although there was significant statistical heterogeneity among studies presumably due to different rates of prior exposure to the agents.
        </p>
        <p>
         Similar findings were noted in the Ongoing
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          Telmisartan
         </a>
         Alone and in Combination With
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          Ramipril
         </a>
         Global Endpoint Trial (ONTARGET) [
         <a href="#rid3">
          3
         </a>
         ]. Cough severe enough to require permanent discontinuation was significantly less common with telmisartan (1.1 versus 4.2 percent with ramipril, relative risk 0.26), despite an identical run-in period.
        </p>
        <p>
         This benefit of ARBs also applies to patients with a prior history of ACE inhibitor-induced cough. This was illustrated in a randomized trial in which 135 such patients were randomly assigned to repeat therapy with an ACE inhibitor (
         <a class="drug drug_general" data-topicid="9565" href="/z/d/drug information/9565.html" rel="external">
          lisinopril
         </a>
         ),
         <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">
          valsartan
         </a>
         , or
         <a class="drug drug_general" data-topicid="8529" href="/z/d/drug information/8529.html" rel="external">
          hydrochlorothiazide
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ]. The rate of recurrent cough was much higher with readministration of an ACE inhibitor (67 versus 19 percent with the other drugs).
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Angioedema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Available evidence suggests the rate of angioedema with ARB therapy is low. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16380.html" rel="external">
          "ACE inhibitor-induced angioedema", section on 'Future use of related drugs'
         </a>
         .)
        </p>
        <p>
         ARBs appear be safe in patients with symptomatic asthma. In one report,
         <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">
          candesartan
         </a>
         did not induce cough or worsen bronchial hyperreactivity in such patients [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3831.html" rel="external">
          "Treatment of hypertension in asthma and COPD"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Hypotension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypotensive symptoms appear to be more common with ARBs than ACE inhibitors. The magnitude of this effect was illustrated in the ONTARGET trial cited above in which hypotensive symptoms severe enough to require permanent discontinuation occurred significantly more often with
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          telmisartan
         </a>
         (2.7 versus 1.7 percent with
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         , relative risk 1.54). These permanent discontinuations occurred despite a run-in period in which both telmisartan and ramipril were prescribed before randomization [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Avoid in pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with ACE inhibitors, ARBs are contraindicated in pregnancy [
         <a href="#rid51">
          51,52
         </a>
         ]. An additional concern is that AT1 receptor blockade results in the disinhibition of renin release by angiotensin II and increased formation of all angiotensin peptides [
         <a href="#rid46">
          46
         </a>
         ]. These peptides could activate the AT2 receptor, which is highly expressed in the fetus.
        </p>
        <p class="headingAnchor" id="H14233849">
         <span class="h2">
          Enteropathy with olmesartan
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 2013, the United States Food and Drug Administration (FDA) reported that
         <a class="drug drug_general" data-topicid="10061" href="/z/d/drug information/10061.html" rel="external">
          olmesartan
         </a>
         can produce a "sprue-like enteropathy" characterized by severe chronic diarrhea and weight loss, occurring months to years after initiation of the drug [
         <a href="#rid53">
          53
         </a>
         ]. In many cases, intestinal biopsy revealed villous atrophy, and, in all cases, antibody testing for celiac disease was negative [
         <a href="#rid54">
          54
         </a>
         ]. The condition resolved after discontinuation of olmesartan, but rechallenge with the drug sometimes reproduced the symptoms.
        </p>
        <p>
         The largest experience comes from a French cohort of 4,546,680 patients who initiated therapy with
         <a class="drug drug_general" data-topicid="10061" href="/z/d/drug information/10061.html" rel="external">
          olmesartan
         </a>
         , or a different ARB, or an ACE inhibitor [
         <a href="#rid55">
          55
         </a>
         ]. Compared with users of ACE inhibitors, intestinal malabsorption severe enough to cause hospitalization occurred substantially more often among patients taking olmesartan for one to two years (adjusted risk ratio 3.7, 95% CI 1.8-7.3) and among those taking olmesartan for more than two years (adjusted risk ratio 10.6, 95% CI 5.0-22.5; the corresponding two-year number needed to harm was 12,550 treated to cause one additional case of severe enteropathy) [
         <a href="#rid56">
          56
         </a>
         ]. Risk was not increased in users of other ARBs.
        </p>
        <p>
         Thus, patients starting
         <a class="drug drug_general" data-topicid="10061" href="/z/d/drug information/10061.html" rel="external">
          olmesartan
         </a>
         should be cautioned about the possibility of developing diarrhea and weight loss. The drug should be stopped if these symptoms occur and another cause is not found.
        </p>
        <p class="headingAnchor" id="H8990691">
         <span class="h2">
          Cancer and myocardial infarction risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2010 meta-analysis of five trials of almost 62,000 patients suggested that patients treated with ARBs had a significantly increased risk of new cancers compared with patients in control groups (7.2 versus 6.0 percent, risk ratio 1.08, 95% CI 1.01-1.15) [
         <a href="#rid57">
          57
         </a>
         ]. However, two subsequent meta-analyses failed to confirm this finding [
         <a href="#rid58">
          58,59
         </a>
         ]. One of these studies included 15 trials of almost 140,000 patients [
         <a href="#rid59">
          59
         </a>
         ]. The cancer incidence was similar in patients treated with ARBs and controls, some of whom were treated with ACE inhibitors (6.2 versus 6.3 percent, odds ratio 1.00, 95% CI 0.95-1.04). In June of 2011, the US FDA reviewed the available data and concluded that the use of ARBs for the treatment of hypertension does
         <strong>
          not
         </strong>
         increase the risk of cancer [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
         Years later, large-scale recalls of specific lots of several different ARBs were triggered by the discovery of potentially carcinogenic nitrosamines in the pills, presumably formed by a side reaction during the manufacturing process [
         <a href="#rid61">
          61
         </a>
         ]. The US FDA estimated that one additional case of cancer would be expected for every 8000 patients taking the highest dose of
         <a class="drug drug_general" data-topicid="10036" href="/z/d/drug information/10036.html" rel="external">
          valsartan
         </a>
         for four years. Continued vigilance is required to protect the public from these impurities.
        </p>
        <p>
         The issue of cancer risk in patients receiving combination therapy with ACE inhibitors and ARBs is discussed below. (See
         <a class="local">
          'Possible increased risk of cancer'
         </a>
         below.)
        </p>
        <p>
         A 2004 report suggested an increased risk of myocardial infarction among users of ARBs [
         <a href="#rid62">
          62
         </a>
         ]. However, a subsequent meta-analysis of data from 37 randomized controlled trials showed no increase in risk [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          ACE INHIBITORS VERSUS ARBS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best comparative data regarding the incidence of side effects observed with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) come from the randomized Ongoing
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          Telmisartan
         </a>
         Alone and in Combination With
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          Ramipril
         </a>
         Global Endpoint Trial (ONTARGET) of over 25,000 patients at high risk for cardiovascular events (diabetes or vascular disease), which compared telmisartan to ramipril or both drugs [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         In terms of side effects, ONTARGET primarily presented data related to adverse effects of sufficient severity to require permanent discontinuation of the drug. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          Ramipril
         </a>
         and
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          telmisartan
         </a>
         had similar rates of hyperkalemia, defined as a serum potassium greater than 5.5 mEq/L (3.3 and 3.4 percent), acute kidney injury, defined as a doubling of the serum creatinine (1.9 and 2.0 percent), and syncope requiring drug discontinuation (0.2 percent with both drugs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of drug discontinuation (including episodes that were not permanent) was modestly but significantly lower with
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          telmisartan
         </a>
         than with
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         (23 versus 24.5 percent, relative risk 0.94) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          Ramipril
         </a>
         was associated with significantly higher rates of cough (4.2 versus 1.1 percent) and angioedema (0.3 versus 0.1 percent) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          Telmisartan
         </a>
         was associated with a significantly higher rate of symptomatic hypotension (2.6 versus 1.7 percent) [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          COMBINATION OF ACE INHIBITORS AND ARBS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple studies have demonstrated that patients who are treated with both an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) are at higher risk for adverse effects.
        </p>
        <p class="headingAnchor" id="H140142945">
         <span class="h2">
          Increased adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The supportive data on increased adverse effects come from the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The Ongoing
         <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">
          Telmisartan
         </a>
         Alone and in Combination With
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          Ramipril
         </a>
         Global Endpoint Trial (ONTARGET), described in the preceding section, evaluated ramipril, telmisartan, and combination therapy in over 25,000 patients at high risk for cardiovascular events (diabetes or vascular disease). Combined therapy compared to ramipril alone was associated with significant increases in the following adverse effects that were severe enough to require drug discontinuation: hypotensive symptoms (4.8 versus 1.7 percent), syncope (0.3 versus 0.2 percent), and kidney dysfunction (1.1 versus 0.7 percent) [
         <a href="#rid3">
          3,64
         </a>
         ]. There was also a significant increase in hyperkalemia, defined as a serum potassium above 5.5 mEq/L (5.7 versus 3.3 percent), and an almost significant increase in overall mortality (12.5 versus 11.8 percent with ramipril alone, risk ratio 1.07, 95% CI 0.98-1.16).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An increased incidence of adverse events with combination therapy was also demonstrated in a meta-analysis of four randomized trials that compared 17,337 patients with chronic heart failure who received either an ACE inhibitor alone or the combination of an ACE inhibitor and an ARB [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'General cautions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Compared with patients who received an ACE inhibitor alone, those treated with both agents had significantly higher rates of the following complications: increased medication discontinuation due to adverse effects (15 versus 11 percent); worsening kidney function, defined as an increase in creatinine of 0.5 mg/dL (44.2 micromol/L) or more over baseline (3.3 versus 1.5 percent); hyperkalemia (3.5 versus 0.7 percent); and symptomatic hypotension (2.4 versus 1.5 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H140142902">
         <span class="h3">
          Possible increased risk of cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a meta-analysis of trials of antihypertensive drugs, combination therapy with ARBs and ACE inhibitors compared with ACE inhibitors alone was associated with a significant increase in cancer incidence among 28,168 patients from two trials (2.3 versus 2.0 percent; risk ratio 1.14, 95% CI 1.02-1.28) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         By contrast, a second meta-analysis that included these two trials as well as five others found similar rates of cancer incidence in patients treated with combination therapy compared with ACE inhibitors alone (5.33 versus 5.26 percent) [
         <a href="#rid59">
          59
         </a>
         ]. However, there was significant heterogeneity among the seven trials. The cancer incidence tended to be higher with combination therapy in three trials (at a mean follow-up of 48 months) and somewhat lower with combination therapy in the other four trials (at a mean follow-up of 32 months).
        </p>
        <p class="headingAnchor" id="H140142921">
         <span class="h2">
          Conclusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon the clear evidence of possible harm, combined ACE inhibitor/ARB therapy should
         <strong>
          not
         </strong>
         be considered unless there is compelling evidence of clinical benefit that cannot be attained with other regimens [
         <a href="#rid65">
          65
         </a>
         ]. Similar recommendations apply to the combination of a direct renin inhibitor with an ACE inhibitor or an ARB [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8527524">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16828.html" rel="external">
          "Patient education: Side effects from medicines (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H939716">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Side effects that occur with angiotensin-converting enzyme (ACE) inhibitors are related to either reduced angiotensin II formation or increased kinins. Those related to reduced angiotensin II formation include hypotension, acute kidney injury, hyperkalemia, and problems during pregnancy. Side effects thought to be related, at least in part, to increased kinins include cough, angioedema, and anaphylactoid reactions. (See
         <a class="local">
          'ACE inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperkalemia and kidney injury may require termination of the ACE inhibitor. Termination should be considered if hyperkalemia cannot be controlled or the serum creatinine concentration increases more than 30 percent above the baseline value within the first six to eight weeks when blood pressure is reduced. (See
         <a class="local">
          'Reduction in GFR'
         </a>
         above and
         <a class="local">
          'Hyperkalemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiotensin II receptor blockers (ARBs) are associated with lower rates of cough and angioedema and a higher rate of hypotensive symptoms. (See
         <a class="local">
          'ARBs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A dry cough occurs in 5 to 20 percent of patients treated with an ACE inhibitor and approximately one-third as many patients treated with an ARB. Treatment consists of lowering the dose or discontinuing the drug. Readministration of the drug is associated with a high rate of recurrent cough. (See
         <a class="local">
          'Cough'
         </a>
         above and
         <a class="local">
          'Incidence of cough with ARBs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angioedema is a rare but potentially fatal complication of ACE inhibitors. Angioedema may also occur with ARBs, but the risk is lower. (See
         <a class="local">
          'Angioedema and anaphylactoid reactions'
         </a>
         above and
         <a class="local">
          'Angioedema'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are on both an ACE inhibitor and an ARB are at higher risk for adverse effects. Thus, combined therapy should
         <strong>
          not
         </strong>
         be considered in the treatment of hypertension or other disorders unless there is compelling evidence of benefit. (See
         <a class="local">
          'Combination of ACE inhibitors and ARBs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ACE inhibitors and ARBs are contraindicated in pregnancy. (See
         <a class="local">
          'Avoid in pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011; 13:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor AA, Siragy H, Nesbitt S. Angiotensin receptor blockers: pharmacology, efficacy, and safety. J Clin Hypertens (Greenwich) 2011; 13:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostis JB, Shelton B, Gosselin G, et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toto RD, Mitchell HC, Lee HC, et al. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann Intern Med 1991; 115:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685.
          </a>
         </li>
         <li class="breakAll">
          Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stirling C, Houston J, Robertson S, et al. Diarrhoea, vomiting and ACE inhibitors:--an important cause of acute renal failure. J Hum Hypertens 2003; 17:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choudhri AH, Cleland JG, Rowlands PC, et al. Unsuspected renal artery stenosis in peripheral vascular disease. BMJ 1990; 301:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannedouche T, Godin M, Fries D, Fillastre JP. Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. Nephron 1991; 57:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. Endocrinology 1991; 129:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998; 158:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desai AS, Swedberg K, McMurray JJ, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 2007; 50:1959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knoll GA, Sahgal A, Nair RC, et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002; 112:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han SW, Won YW, Yi JH, Kim HJ. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant 2007; 22:1150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phakdeekitcharoen B, Leelasa-nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 2004; 44:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panese S, Mártin RS, Virginillo M, et al. Mechanism of enhanced transcellular potassium-secretion in man with chronic renal failure. Kidney Int 1987; 31:1377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hörl MP, Hörl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood R. Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study. Br J Clin Pharmacol 1995; 39:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010; 123:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo WW, Chadwick IG, Kraskiewicz M, et al. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. Br J Clin Pharmacol 1995; 40:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994; 308:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malini PL, Strocchi E, Zanardi M, et al. Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor. Lancet 1997; 350:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilchrist NL, Richards AM, March R, Nicholls MG. Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study. J Hum Hypertens 1989; 3:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dicpinigaitis PV. Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenenbaum A, Grossman E, Shemesh J, et al. Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am J Hypertens 2000; 13:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004; 4:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fogari R, Zoppi A, Tettamanti F, et al. Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 1992; 19:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sica DA. Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations. J Clin Hypertens (Greenwich) 2004; 6:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasoul S, Carretero OA, Peng H, et al. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004; 22:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulhern JG, Lipkowitz GS, Braden GL, et al. Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition. Am J Nephrol 1995; 15:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001; 72:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plata R, Cornejo A, Arratia C, et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet 2002; 359:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29:2273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bexelius TS, Ljung R, Mattsson F, et al. Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case-control study in Sweden. BMC Gastroenterol 2017; 17:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouette J, Yin H, McDonald EG, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study. Drug Saf 2022; 45:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twohig PA, de-Madaria E, Thakkar S, et al. Quantifying the Risk of Drug-Induced Pancreatitis With Angiotensin-Converting Enzyme Inhibitors and Statins Using a Large Electronic Medical Record Database. Pancreas 2021; 50:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dabaghi S. ACE inhibitors and pancreatitis. Ann Intern Med 1991; 115:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lip GY, Ferner RE. Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors. J Hum Hypertens 1995; 9:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HY, Kim CH. Acute oliguric renal failure associated with angiotensin II receptor antagonists. Am J Med 2001; 111:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacourcière Y, Brunner H, Irwin R, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group. J Hypertens 1994; 12:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka H, Teramoto S, Oashi K, et al. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. Circulation 2001; 104:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet 2001; 357:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serreau R, Luton D, Macher MA, et al. Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 2005; 112:710.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm (Accessed on July 09, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ianiro G, Bibbò S, Montalto M, et al. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014; 40:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basson M, Mezzarobba M, Weill A, et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 2016; 65:1664.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talley NJ. Use of olmesartan for ≥ 1 year was associated with hospitalization for intestinal malabsorption. Ann Intern Med 2015; 163:JC13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011; 12:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 2011; 29:623.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257670.htm (Accessed on June 15, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JB, Chertow GM, Bhalla V. Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls. N Engl J Med 2019; 380:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004; 329:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 2011; 342:d2234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holdiness A, Monahan K, Minor D, de Shazo RD. Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations. Am J Med 2011; 124:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3816 Version 38.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21896148" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Angiotensin-converting enzyme inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21896150" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Angiotensin receptor blockers: pharmacology, efficacy, and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378520" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Telmisartan, ramipril, or both in patients at high risk for vascular events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8579032" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1883120" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10724055" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10724055" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12764405" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Diarrhoea, vomiting and ACE inhibitors:--an important cause of acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2261558" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Unsuspected renal artery stenosis in peripheral vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2020353" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1855477" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9437375" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17996561" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17923591" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295047" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11835948" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17255126" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15384026" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3613409" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Mechanism of enhanced transcellular potassium-secretion in man with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15250920" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Drug therapy for hypertension in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1616218" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7619667" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21035591" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8703645" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8298346" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9217714" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Thromboxane antagonism and cough induced by angiotensin-converting-enzyme inhibitor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2691690" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of sulindac on angiotensin converting enzyme inhibitor-induced cough: randomised placebo-controlled double-blind cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8913404" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10933569" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15238791" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1381763" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effects of nifedipine and indomethacin on cough induced by angiotensin-converting enzyme inhibitors: a double-blind, randomized, cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7717281" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17984484" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249800" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Angiotensin-converting enzyme inhibitors side effects--physiologic and non-physiologic considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15076166" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7573190" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Association of post-renal transplant erythrocytosis and microalbuminuria: response to angiotensin-converting enzyme inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502994" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11879862" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21970934" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14751650" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28270103" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Angiotensin II receptor blockers and risk of acute pancreatitis - a population based case-control study in Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34714528" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Acute Pancreatitis: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34714286" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Quantifying the Risk of Drug-Induced Pancreatitis With Angiotensin-Converting Enzyme Inhibitors and Statins Using a Large Electronic Medical Record Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1649564" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : ACE inhibitors and pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8551483" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10696996" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Angiotensin II receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295051" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11501548" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Acute oliguric renal failure associated with angiotensin II receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7706699" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11457745" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11211003" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Losartan and fetal toxic effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15924524" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15924524" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24805127" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Systematic review: Sprue-like enteropathy associated with olmesartan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26250345" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26666803" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Use of olmesartan for≥ 1 year was associated with hospitalization for intestinal malabsorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20542468" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21123111" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358417" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358417" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30865819" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15564232" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Angiotensin receptor blockers and myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21521728" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18707986" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21187182" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23121378" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
